Non-Muscle-invasive Bladder Cancer (NMIBC) Recruiting Phase 1 Trials for Enfortumab vedotin (DB13007)

Also known as: Non-Muscle- Invasive Bladder Cancer / NMIBC / Non-muscle Invasive Bladder Cancer / Non Muscle-invasive Bladder Cancer / Non-muscle-invasive Bladder Cancer / Non-muscle Invasive Bladder Cancer (NMIBC) / Non Muscle Invasive Bladder Cancer / Nonmuscle Invasive Bladder Cancer / Non-Muscle Invasive Bladder Neoplasms / Carcinoma of urinary bladder, superficial (disorder) / Urothelial carcinoma bladder / Bladder transitional cell carcinoma / Transitional cell carcinoma of bladder (disorder)

IndicationStatusPhase
DBCOND0082324 (Non-Muscle-invasive Bladder Cancer (NMIBC))Recruiting1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT05014139
A Study of Intravesical Enfortumab Vedotin For Treatment of Patients With Non-muscle Invasive Bladder Cancer (NMIBC)Treatment